CHAMPIGNON BRANDS’ CANADIAN RAPID TREATMENT CENTER OF EXCELLENCE OPENS FIRST COMMUNITY-BASED CENTRE IN OTTAWA TO PROVIDE KETAMINE TREATMENT FOR ADULTS WITH DEPRESSION
Third CRTCE Clinic effectively addresses the unmet need of depression and suicide
VANCOUVER, BRITISH COLUMBIA – Monday, January 25, 2021 – Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), Chairman and CEO Roger McIntyre today announced the opening of a new Canadian Rapid Treatment Center of Excellence (CRTCE) clinic in Ottawa, Ontario. This third clinic joins the Mississauga and Toronto clinics (CRTCE Clinics) in addressing the unmet need of depression and suicide through novel ketamine therapy treatment.
“Over twenty clinical trials have demonstrated that ketamine and esketamine have rapid and robust antidepressant effects in patients that have failed to respond to conventional antidepressants. During the COVID-19 pandemic, the need for effective treatment has become exponentially critical,” said Dr. Joshua Rosenblat, Medical Director, CRTCE. “Ketamine treatment for depression is very difficult to access in Canada. This third clinic should allow more people to access treatment.”
The first of its kind in Canada, the CRTCE multidisciplinary outpatient clinical research facility has specialized in providing breakthrough rapid onset treatments for depression, including but not limited to intravenous ketamine and intranasal esketamine. These therapies aid patients suffering from several treatment-resistant conditions such as major depressive disorder and/or bipolar disorder.
“In just 30 months through the two current CRTCE Clinics we have administered more than 2500 Intravenous Ketamine Infusions and over 60 Intranasal Ketamine treatments. Many of these patients have experienced substantial relief for what often can be debilitating depression and suicidal thinking,” said Kevin Kratiuk, Vice President of Operations, CRTCE.
To obtain treatment, patients must be referred to one of the CRTCE Clinics by family physicians, psychiatrists, or nurse practitioners. Patients with PTSD and OCD are considered on a case-by-case basis. Kratiuk continued, “This newest clinic will expand our capacity to help more people affected by depression”.
The new Ottawa clinic is in Ottawa’s Alta Vista neighbourhood. “The opening of our first Ottawa CRTCE Clinic provides an opportunity for CRTCE to provide access to new treatments for people who are suffering from depression. In addition to providing clinical care, all CRTCE Clinics conduct research that aims to improve the quality of people’s lives affected by these common and debilitating disorders in Canada,” said Dr. Roger McIntyre, CEO Champignon Brands Inc., Professor of Psychiatry and Pharmacology University of Toronto.
Founded in July 2018, Canadian Rapid Treatment Center of Excellence (CRTCE) (https://www.crtce.com/) is an all-Canadian company. It operates clinics in Mississauga and Toronto and now in Ottawa.
CRTCE provides a platform for treatment development identification of and implementation breakthrough derivatives of ketamine and psychedelics, and innovative delivery platforms for the purpose of treating medical disorders like depression, post-traumatic stress disorder (PTSD) as well as substance and alcohol use disorder.
The CRTCE Clinics offer Intravenous Ketamine Infusion Therapy, Intranasal EsKetamine Therapy and Sublingual/ Oral Ketamine Therapy – all aimed at aiding those suffering from several treatment-resistant conditions. The clinic provides a comfortable environment focused on the safety and success of each individual patient.
Champignon Brands Inc. (http://braxiascientific.com) is a research-driven company specializing in breakthrough ketamine treatment for depression and other mental health conditions. The Company works closely with subsidiaries including AltMed Capital Corp. (“AltMed”). The Canadian Rapid Treatment Center of Excellence is wholly owned by AltMed.
ON BEHALF OF THE BOARD
“Dr. Roger S. McIntyre”
Dr. Roger S. McIntyre
Chairman & CEO
Media: Victoria Ollers, [email protected], 416 822-2288
Call emergency medical services immediately if you believe you are experiencing a medical emergency. Do not rely on communication through the Champignon Brands website of the emails/telephone numbers above for urgent medical needs. Champignon Brands Inc. does not provide medical advice. If you have any specific medical questions or are seeking advice, please consult with your health care provider.
The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.
Forward-looking Information Cautionary Statement
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability, the Company’s limited operating history and lack of historical profits; competition; failure of treatments to provide the expected health benefits; unanticipated side effects; dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, state, municipal, local or other licenses; developments and changes in laws and regulations, including increased regulation of the Company’s industries and the capital markets; economic and financial conditions; volatility in the capital markets; engaging in activities that could be later determined to be illegal under domestic or international laws; failure to obtain the necessary shareholder, government or regulatory approvals, including that of the CSE; and failure to retain, secure and maintain key personnel and strategic partnerships including but not limited to executives, researchers, clinicians, customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available.
Symbols – CSE: BRAX OTC: BRAXF FWB: 496